Imexon augments sensitivity of human lymphoma cells to ionizing radiation: In vitro experimental study

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4409-4415

  Cho, Heunglae ^a   Koto, Masashi ^b   Riesterer, Oliver ^c   Molkentine, David P ^d   Giri, Uma ^d   Milas, Luka ^d   Story, Michael D ^e   Ha, Chul S ^f   Raju, Uma ^d  

^a Inje University   (South Korea)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f University of Texas Health Science Center   (United States)

Author keywords

Antiproliferative activity; Imexon antioxidant; Ionizing radiation; Lymphoma cells; Radiosensitization

Indexed keywords

CASPASE 3; GLUTATHIONE; IMEXON; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IONIZING RADIATION; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RADIOSENSITIZATION; RAJI CELL; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; HEXANONES; HUMANS; LYMPHOMA, NON-HODGKIN; LYMPHOMA, T-CELL; OXIDATION-REDUCTION; RADIATION-SENSITIZING AGENTS;

EID: 75149188674     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R and Salmon SE: Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. J Natl Cancer Inst 84: 1238-1244, 1992.
2. Bicker U and Fuhse P: Carcinostatic action of 2-cyanaziridines against a sarcoma in rats. Exp Pathol (Jena) 10: 279-284,1975.
3. Dvorakova K, Payne CM, Landowski TH,Tome ME, Halperin DS and Dorr RT: Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anticancer Drugs 13: 1031-1042, 2002.
4. Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E and Dorr R: Phase I trial of imexon in patients with advanced malignancy. J Clin Oncol 25: 1779-1784, 2007.
5. Dorr RT, Liddil JD, Klein MK and Hersh EM: Preclinical pharmacokinetics and antitumor activity of imexon. Invest New Drugs 15: 113-116, 1995.
6. Hersh EM, Grogan TM, Funk CY and Taylor CW: Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy. J Immunother Emphasis Tumor Immunol 15: 77-83,1993.
7. Kreienberg R, Boerner D, Melchert F and Lemmel EM: Reduction of the immunosuppressive action of chemotherapeutics in patients with mammary carcinoma by azimexon. J Immunopharmacol 5: 49-64, 1983.
8. Patt YZ, Mavligit GM, Reuben J, Mansell PW, Li S, Newell G, Talpaz M and Hersh EM: Modulation in vitro of immune parameters in homosexual males with the preclinical complex of symptoms related to acquired immune deficiency syndrome by azimexon. J Biol Response Mod 5: 263-269, 1986.
9. Funk CY, Eisman J and Hersh EM: Treatment of the murine, retrovirus-induced lymphoproliferative immunodeficiency disease (LP-BM5) in C57BL/10 mice with the immunomodulator imexon. AIDS Res Hum Retroviruses 8: 633-638, 1992.
10. Salmon SE and Hersh EM: Sensitivity of multiple myeloma to imexon in the human tumor cloning assay. J Natl Cancer Inst 86: 228-230, 1994.
11. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T and Dorr RT: Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 60: 749-758, 2000.
12. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM and Dorr RT: Induction of mitochondrial changes in myeloma cells by imexon. Blood 97: 3544-3551, 2001.
13. Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, Coon A and Dorr RT: Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Mol Cancer Ther 1: 185-195, 2002.
14. Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI and Gartenhaus RB: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 10: 1481-1491, 2004.
15. Samulitis BK, Landowski TH and Dorr RT: Correlates of imexon sensitivity in human multiple myeloma cell lines. Leuk Lymphoma 47: 97-109, 2006.
16. Scott J, Dorr RT, Samulitis B and Landowski TH: Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol 59: 749-757, 2007.
17. Iyengar BS, Dorr RT and Remers WA: Chemical basis for the biological activity of imexon and related cyanoaziridines. J Med Chem 47: 218-223, 2004.
18. Arrick BA and Nathan CF: Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 44: 4224-4232, 1984.
19. Jensen LH, Renodon-Corniere A, Wessel I, Langer SW, Sokilde B, Carstensen EV, Sehested M and Jensen PB: Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition. Mol Pharmacol 61: 1235-1243, 2002.
20. Dynlacht JR, Henthorn J, O'Nan C, Dunn ST and Story MD: Flow cytometric analysis of nuclear matrix proteins: method and potential applications. Cytometry 24: 348-359, 1996.
21. Reed IJ and Muench H: A simple method of estimating fifty percent endpoints. Am J Hygiene 27: 493-497, 1938.
22. Hissin PJ and Hilf R: A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74: 214-226, 1976.
23. Raju U, Gumin GJ, Noel F and Tofilon PJ: IκBα degradation is not a requirement for the X-ray-induced activation of nuclear factor κB in normal rat astrocytes and human brain tumour cells. Int J Radiat Biol 74: 617-624, 1998.
24. 2 phase of the cell cycle. Radia;t Res 150: S52-59, 1998.
25. Dai J, Weinberg RS, Waxman S and Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93: 268-277, 1999.
26. Gartenhaus RB, Prachand SN, Paniaqua M, Li Y and Gordon LI: Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin Cancer Res 8: 566-572, 2002.
27. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG and Waxman S: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94: 2102-2111, 1999.
28. Mantymaa P, Guttorm T, Siitonen T, Saily M, Savolainen ER, Levonen AL, Kinnula V and Koistinen P: Cellular redox state and its relationship to the inhibition of clonal cell growth and the induction of apoptosis during all-trans retinoic acid exposure in acute myeloblastic leukemia cells. Haematologica 85: 238-245, 2000.
29. Griffith OW and Meister A: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-N-buty1 homocysteine sulfoximine). J Biol Chem 254: 7558-7560, 1979.
30. Meister A: Glutathione metabolism and its selective modification. J Biol Chem 263: 17205-17208, 1988.
31. Arrick BA, Nathan CF, Griffith OW and Cohn ZA: Glutathione depletion sensitizes tumor cells to oxidative cytolysis. J Biol Chem 257: 1231-1237, 1982.
32. Gordon LI, Weiss D, Prachand S and Weitzman SA: Scavenging of superoxide anion by phosphorylethanolamine: studies in human neutrophils and in a cell free system. Free Radic Res Commun 15: 65-71, 1991.
33. Nathan CF, Arrick BA, Murray HW, DeSantis NM and Cohn ZA: Tumor cell antioxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med 153: 766-782, 1981.
34. Okada H and Mak TW: Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 4: 592-603, 2004.
35. Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A and Powis G: The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clin Cancer Res 13: 3388-3394, 2007.